The Analysis Study of The Impact of Metformin on The Survival Rate of Pancreatic Cancer: A Comprehensive Systematic Review

Abstract

Background: Pancreatic cancer is one of the most challenging malignancies to treat, with a starkly low 5-year survival rate of 3-6% and a median survival time of less than six months. Recent research indicates that metformin might reduce the incidence of pancreatic cancer in patients with T2DM. Methods: Following PRISMA 2020 guidelines, this systematic review focused exclusively on full-text articles published in English between 2014 and 2024. Result: The study conducted a comprehensive review of over 100 publications sourced from reputable databases, including ScienceDirect, SagePub, and PubMed. Following an initial screening, eight publications were identified as warranting more in-depth analysis. Consequently, a thorough review of these selected studies was performed to ensure a detailed and rigorous evaluation. Conclusion: Metformin appears to offer significant survival benefits to pancreatic cancer patients, particularly those in earlier stages. However, its effectiveness diminishes as the tumor progresses. Epidemiological and laboratory studies have suggested that metformin has antitumor effects.